The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI
Open accessAbstract
OBJECTIVES: Studies evaluating the correlation between the widely used Simple Endoscopic Score for Crohn's disease (SES-CD) and noninvasive markers are scarce. The aim of this study was to evaluate the correlation between the SES-CD and fecal calprotectin, C-reactive protein (CRP), blood leukocytes, and the Crohn's disease activity index (CDAI). METHODS: Crohn's disease patients undergoing complete ileocolonoscopy were prospectively enrolled and scored independently according to the SES-CD and the CDAI. SES-CD was defined as follows: inactive 0-3; mild 4-10; moderate 11-19; and high > or =20. RESULTS: Values in CD patients (n=140 ileocolonoscopies) compared with controls (n=43) are as follows: calprotectin, 334+/-322 vs. 18+/-5 microg/g; CRP, 26+/-29 vs. 3+/-2 mg/l; and blood leukocytes, 9.1+/-3.4 vs. 5.4+/-1.9 g/l (all P<0.001). The SES-CD correlated closest with calprotectin (Spearman's rank correlation coefficient r=0.75), followed by CRP (r=0.53), blood leukocytes (r=0.42), and the CDAI (r=0.38). Calprotectin was the only marker that could discriminate inactive endoscopic disease from mild activity (104+/-138 vs. 231+/-244 microg/g, P<0.001), mild from moderate activity (231+/-244 vs. 395+/-256 microg/g, P=0.008), and moderate from high activity (395+/-256 vs. 718+/-320 microg/g, P<0.001). The overall accuracy for the detection of endoscopically active disease was 87% for calprotectin (cutoff 70 microg/g), 66% for elevated CRP, 54% for blood leukocytosis, and 40% for the CDAI > or =150. CONCLUSIONS: Fecal calprotectin correlated closest with SES-CD, followed by CRP, blood leukocytes, and the CDAI. Furthermore, fecal calprotectin was the only marker that reliably discriminated inactive from mild, moderate, and highly active disease, which underlines its usefulness for activity monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Silverberg, M. S., Satsangi, J., Ahmad, T., Arnott, I. D., Bernstein, C. N., Brant, S. R., Caprilli, R., Colombel, J.-F., Gasche, C., Geboes, K., et al. (2005) · Canadian Journal of Gastroenterology · doi:10.1155/2005/269076 · Cited by 3,409
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Daperno, M., D'Haens, G., Van Assche, G., Baert, F., Bulois, P., Maunoury, V., Sostegni, R., Rocca, R., Pera, A., Gevers, A., et al. (2004) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(04)01878-4 · Cited by 1,774
Hanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Mary, J. Y., & Modigliani, R. (1989) · Gut · doi:10.1136/gut.30.7.983 · Cited by 884
Lichtenstein, G. R., Yan, S., Bala, M., Blank, M., & Sands, B. E. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.048 · Cited by 597
Langhorst, J., Elsenbruch, S., Koelzer, J., Rueffer, A., Michalsen, A., & Dobos, G. J. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01556.x · Cited by 591
Cited by
Maaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., Calabrese, E., Baumgart, D. C., Bettenworth, D., Borralho Nunes, P., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy113 · Cited by 1,823
Self-citationACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,421
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
DʼHaens, G., Ferrante, M., Vermeire, S., Baert, F., Noman, M., Moortgat, L., Geens, P., Iwens, D., Aerden, I., Van Assche, G., et al. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22917 · Cited by 816
Mosli, M. H., Zou, G., Garg, S. K., Feagan, S. G., MacDonald, J. K., Chande, N., Sandborn, W. J., & Feagan, B. G. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.120 · Cited by 690
Khanna, R., Bressler, B., Levesque, B. G., Zou, G., Stitt, L. W., Greenberg, G. R., Panaccione, R., Bitton, A., Paré, P., Vermeire, S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00068-9 · Cited by 460
The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease
Lewis, J. D. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.058 · Cited by 458
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions
Peyrin-Biroulet, L., Panés, J., Sandborn, W. J., Vermeire, S., Danese, S., Feagan, B. G., Colombel, J.-F., Hanauer, S. B., & Rycroft, B. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.06.001 · Cited by 455
Biomarkers of Inflammation in Inflammatory Bowel Disease
Sands, B. E. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.003 · Cited by 405
Menees, S. B., Powell, C., Kurlander, J., Goel, A., & Chey, W. D. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.6 · Cited by 391
Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
Levin, A. D., Wildenberg, M. E., & van den Brink, G. R. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw053 · Cited by 336
Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases
Serriari, N.-E., Eoche, M., Lamotte, L., Lion, J., Fumery, M., Marcelo, P., Chatelain, D., Barre, A., Nguyen-Khac, E., Lantz, O., et al. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12277 · Cited by 334
Meta-analysis: Fecal Calprotectin for Assessment of Inflammatory Bowel Disease Activity
Lin, J.-F., Chen, J.-M., Zuo, J.-H., Yu, A., Xiao, Z.-J., Deng, F.-H., Nie, B., & Jiang, B. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000057 · Cited by 296
Cholapranee, A., Hazlewood, G. S., Kaplan, G. G., Peyrin‐Biroulet, L., & Ananthakrishnan, A. N. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14030 · Cited by 296
A population-based study of fatigue and sleep difficulties in inflammatory bowel disease
Graff, L. A., Vincent, N., Walker, J. R., Clara, I., Carr, R., Ediger, J., Miller, N., Rogala, L., Rawsthorne, P., Lix, L., et al. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21580 · Cited by 294
Chang, J., Leong, R. W., Wasinger, V. C., Ip, M., Yang, M., & Phan, T. G. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.05.056 · Cited by 286
Waugh, N., Cummins, E., Royle, P., Kandala, N.-B., Shyangdan, D., Arasaradnam, R., Clar, C., & Johnston, R. (2013) · Health Technology Assessment · doi:10.3310/hta17550 · Cited by 286
Mitrev, N., Vande Casteele, N., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., Begun, J., Bryant, R., Chan, W., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14368 · Cited by 282
Wright, E. K., Kamm, M. A., De Cruz, P., Hamilton, A. L., Ritchie, K. J., Krejany, E. O., Leach, S., Gorelik, A., Liew, D., Prideaux, L., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.01.026 · Cited by 280
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders
Metwaly, A., Reitmeier, S., & Haller, D. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00581-2 · Cited by 264
Agrawal, M., Spencer, E. A., Colombel, J.-F., & Ungaro, R. C. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.063 · Cited by 261
Converging goals of treatment of inflammatory bowel disease from clinical trials and practice
Levesque, B. G., Sandborn, W. J., Ruel, J., Feagan, B. G., Sands, B. E., & Colombel, J.-F. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.08.003 · Cited by 217
A mountable toilet system for personalized health monitoring via the analysis of excreta
Park, S.-M., Won, D. D., Lee, B. J., Escobedo, D., Esteva, A., Aalipour, A., Ge, T. J., Kim, J. H., Suh, S., Choi, E. H., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0534-9 · Cited by 175
Gracie, D. J., Williams, C. J. M., Sood, R., Mumtaz, S., Bholah, H. M., Hamlin, J. P., & Ford, A. C. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.59 · Cited by 173
Targownik, L. E., Sexton, K. A., Bernstein, M. T., Beatie, B., Sargent, M., Walker, J. R., & Graff, L. A. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.147 · Cited by 157
Positioning and usefulness of biomarkers in inflammatory bowel disease
Sakurai, T., & Saruta, M. (2023) · Digestion · doi:10.1159/000527846 · Cited by 156
Manolakis, A. C., Kapsoritakis, A. N., Tiaka, E. K., & Potamianos, S. P. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1494-9 · Cited by 96
Resolution of inflammation in inflammatory bowel disease
Rogler, G. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30031-6 · Cited by 79
Gray, M. A., Chao, C.-Y., Staudacher, H. M., Kolosky, N. A., Talley, N. J., & Holtmann, G. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193542 · Cited by 63
Berrill, J. W., Gallacher, J., Hood, K., Green, J. T., Matthews, S. B., Campbell, A. K., & Smith, A. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12219 · Cited by 62
What Is a Flare? The Manitoba Living With IBD Study
Witges, K., Sexton, K., Graff, L. A., Targownik, L. E., Lix, L. M., Haviva, C., Stone, J., Shafer, L. A., Vagianos, K., & Bernstein, C. N. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab192 · Cited by 15
Metadata
- Authors
- Schoepfer, A. M., Beglinger, C., Straumann, A., Trummler, M., Vavricka, S. R., Bruegger, L. E., & Seibold, F.
- Venue
- American Journal of Gastroenterology
- Published
- 2010-01
- Volume
- 105
- Issue
- 1
- Pages
- 162-169
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2089176308
- Cited by
- 570
- References
- 28
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.